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Summary
Congenital disorders of glycosylation (CDG) are a family of N-linked glycosylation defects associated with severe clinical manifestations. In CDG type-I, deficiency of lipid-linked oligosaccharide assembly lead to the under-occupancy of N-glycosylation sites on glycoproteins.
Although the level of residual glycosylation activity is known to correlate with the clinical phenotype linked to individual CDG mutations, it is not known whether the degree of Nglycosylation site occupancy by itself correlates with the severity of the disease. To quantify the extent of underglycosylation in healthy control and in CDG samples, we developed a quantitative method of N-glycosylation site occupancy based on multiple reaction monitoring LC-MS/MS.
Using isotopically labeled standard peptides, we directly quantified the level of N-glycosylation site occupancy on selected serum proteins. In healthy control samples, we determined 98-100% occupancy for all N-glycosylation sites of transferrin and α1-antitrypsin. In CDG type-I samples, we observed a reduction in N-glycosylation site occupancy, which correlated with the severity of the disease. In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein. In transferrin, a preferred occupancy for the first N-glycosylation site was observed and a decreasing preference for the first, third and second N-glycosylation site was observed in α1-antitrypsin. This multiple reaction monitoring LC-MS/MS method can be extended to multiple glycoproteins, thereby enabling a glyco-proteomic survey of N-glycosylation site occupancies in biological samples.
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Introduction
In human, disturbances in the biosynthesis of glycoconjugates lead to diseases with heterogeneous biochemical and clinical characteristics (1) . Deficiencies in the biosynthesis of serine-or threonine-linked (O-linked), asparagines-linked (N-linked), glycosylphosphatidylinositol and glycosphingolipid glycans have been described (2) (3) (4) (5) . Inherited deficiencies in the N-glycosylation biosynthetic pathway are referred to as congenital disorders of glycosylation (CDG). CDGs represent multi-organ diseases involving central and peripheral nervous defects and are often associated with endocrine and coagulation disorders (6) . The heterogeneous symptoms associated to CDG and the structural diversity of glycoconjugate render the identification of glycosylation defects a difficult task. After initial clinical suspicion of CDG, the serum glycoprotein transferrin serves as a biomarker for possible defects of Nglycosylation. The integrity of transferrin N-glycosylation is tested by isoelectric focusing electrophoresis, Western blot analysis and by MS measurements of the purified glycoprotein (7) (8) (9) . Deficiencies of N-glycosylation site occupancy are classified as CDG type-I (CDG-I), whereas defects of N-glycan trimming and elongation are classified as CDG type-II (CDG-II) (10) .
To date, 12 distinct genetic defects, which affect the N-glycosylation output to different levels, have been identified as cause of CDG-I. Mutations in the phosphomannomutase-2 gene represent the most frequent form of CDG-I. The level of residual enzymatic activity associated to individual mutations in the phosphomannomutase-2 gene has been correlated with the severity of the clinical presentations (11) . However, the exact degree of protein underglycosylation in CDG-I has not been determined yet, and it is unclear whether the degree of underglycosylation directly 5 relates to the severity of the disease. Also, the degree of N-glycosylation site occupancy found in healthy individuals has not been defined yet.
To better understand the functional significance of N-glycosylation in humans, a precise measure for the glycosylation site occupancy in healthy and in CDG-related conditions is necessary. In proteomics, the most widely applied experiment for the determination of peptide sequences relies on product ion scanning mass spectrometry (MS/MS). Precursor ions of selected peptides are selected in a first mass analyzer, fragmented in a collision cell and the generated product ion fragments are scanned in a second mass analyzer. Triple quadrupole mass spectrometers are particularly suitable for quantitative determinations of changes in serum protein levels. These instruments allow multiple reaction monitoring (MRM) experiments, a sequential selection of peptide specific precursor ions in the first mass analyzer together with a characteristic fragment ion in the second mass analyzer upon fragmentation in the collision cell. Transitions of precursor to fragment ions lead to signals in the detector and can be recorded as a function of time during chromatographic elution. Additionally, the sequence of eluting peptides can be confirmed by the acquisition of corresponding product ion spectra. The selectivity of the MRM transitions together with short scan times for each transition allow for sensitive, quantitative analyses of complex samples (12, 13) .
In the present study, we describe a MRM LC-MS/MS approach to quantify the N-glycosylation site occupancy of the serum glycoproteins transferrin and α1-antitrypsin. We analyzed 28 serum samples and quantified glycosylation site occupancies in healthy and in disease related samples.
For the first time, we found a clear correlation in CDG-I between the degree of N-glycosylation site occupancy and the severity of the disease.
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Experimental Procedures
Isoelectric focusing gel electrophoresis Serum transferrin was saturated for 30 min with ferric citrate (0.4 mM) in the presence of sodium hydrogen carbonate (20 mM) and separated on a rehydrated Immobiline DryPlate gel (GE Healthcare) with a pH range of 4.0-7.0 using the Phast-System (Amersham Biosciences).
Transferrin was visualized by gel immunoprecipitation using polyclonal rabbit anti-human transferrin antibodies (DakoCytomation). The antibody solution was directly applied onto the gel and incubated for 1h. To remove excess of antibodies and non-bound proteins, the gel was washed over night in 0.9% NaCl, followed by fixation and staining with PhastGel Blue R (GE Healthcare) according to the manufacture protocol.
Immuno-affinity enrichment of glycoproteins from human serum
Serum glycoproteins were purified with a custom made HU-6 multiple affinity removal system column (MARS column, 4.6 x 50 mm, Agilent Technologies), targeting transferrin, IgG and α1-antitrypsin. The purification was performed from 5 μl human serum using the buffers and protocol recommended by the manufacturer. The glycoproteins were eluted into 1 ml fractions and the elution was monitored by UV absorption at 280 nm.
Proteolytic digestion and glycopeptide labeling
The proteins in the collected fractions were precipitated with TCA, pooled with reduction buffer 
Mass spectrometry
An Applied Biosystems QTRAP 3200 LC-MS/MS system, equipped with a NanoSpray II ion source and an Eksigent nanoLC-2D system was used. The sample reaction mixture (2 to 10 μl) 
Results
The serum glycoprotein transferrin is the most widely used biomarker for the clinical diagnosis of CDG-I and -II. Normal serum transferrin typically contains two sialylated, biantennary complex type N-glycans attached to the glycosylation sites at Asp413 and Asp611(14). Serum samples from CDG-I, CDG-II, hereditary fructose intolerance (HFI) and healthy individuals were analyzed by transferrin isoelectric focusing gel electrophoresis and the typical deviations of the band pattering of CDG sera from the healthy controls could be observed (Fig. 1) . A major 9 band corresponding to tetrasialylated, fully glycosylated transferrin was observed in control samples. In CDG sera, undersialylation was detected with more intense bands corresponding to tri-, di-, mono-and asialylated transferrin. In CDG-II, this pattern can be explained by altered trimming and elongation of transferrin N-glycan structures, which leads to decreased transfer of terminal sialic acid. In CDG-I, decreased N-glycosylation site occupancy results in the undersialylation as observed in the transferrin isoelectric focusing gel (Fig. 1) . In HFI the metabolite fructose-1-phosphate accumulates in the liver, which leads to inhibitory effects in early steps of N-glycosylation biosynthesis. Therefore, HFI can be considered as a secondary CDG syndrome and CDG-I typical patterns are observed in transferrin isoelectric focusing gel electrophoresis (15) . Polypeptide polymorphisms of transferrin also lead to altered gel patterning, which can be revealed by sialidase treatment prior isoelectric focusing electrophoresis. To precisely measure the N-glycosylation site occupancy in healthy as well as in pathological conditions, sera from 17 CDG patients, 1 alcohol abuse patient, 1 HFI patient and 9 sera from healthy individuals were selected for analysis. The serum of an alcohol abuse patient was included as a positive control. Alcohol abuse leads to reduced N-glycosylation site occupancy of transferrin, thus mimicking CDG-I(16). The samples were subjected to glycoprotein purification using a custom made multiple affinity column directed against human transferrin, α1-antitrypsin and IgG. The reduced and alkylated proteins were digested with a combination of trypsin and Asp-N and isotopically labeled standard peptides were added(17) ( Table 1) .
at SMAC Consortium -University of Zürich on February 9, 2010 www.mcponline.org 10 Table 1   Table 2 An isotope label was introduced into N-glycosylated sample peptides with PNGaseF in H 2 18 O buffer. PNGaseF deglycosylates Asn-linked glycopeptides and converts the corresponding Asn to Asp. In the presence of H 2 18 O buffer 18 O is incorporated into the carboxyl-group of the newly formed Asp (18, 19) . The added standard peptides were synthesized according to the transferrin and α1-antitrypsin N-glycosylation site sequences with either Asn or Asp introduced into the Nglycosylation sequon. The precursor and fragment ion pairs used for each MRM transition were selected empirically based on maximal signal intensities and signal specificities as judged from the chromatography of extracted ion pairs (Table 2 ). For the sample peptides, the corresponding precursor ion and fragment ion types as selected for the standard peptides were used. The inclusion of the standard peptides facilitated the identification and quantitation of Nglycosylation site occupancy with LC-MS/MS. The peptide mixture was separated on a reversephase nanoLC column and introduced to the mass spectrometer via a nanoelectrospray ion source. The chromatography was monitored from the total ion chromatogram (Fig. 2) . MRM transitions for each target peptide and the fragment ion spectra of the corresponding sample peptides were recorded sequentially. The acquisition was grouped into three time periods according to the elution positions of the second and the first transferrin target peptides and the elution positions of the α1-antitrypsin target peptides, respectively (Fig. 2) . Figure 2 11
The MRM transitions together with the co-elutions of the sample peptides with the labeled standard peptides served as primary criteria for peptide identification. In addition, the enhanced product ion spectra of the sample peptides were acquired and the peptide sequences were deduced from the fragment spectra by comparison with previously recorded fragment ion spectra of the corresponding standard peptides (Fig. 3) . The average signal intensities of the sample and standard peptides were used to calculate the site occupancies of each glycosylation site (Fig. 4) . Overall, the sensitivity for detection of each peptide was depending on their ionization characteristics, and was partially accounted for in adjusted dwell times of the respective MRM transition (between 20 and 200 ms, Table 2 ). The results are summarized in Table 3 . The site occupancy for all detected N-glycosylation sites in the healthy control samples ranged between 98 and 100%. The transferrin glycosylation sites are equally occupied under normal physiological conditions. In α1-antitrypsin, the first and the third N-glycosylation sites were always occupied to 100%, whereas the second N-glycosylation site appeared slightly less stringently occupied with an average of 99 ± 1.4% under normal physiological conditions.
The level of site occupancy in CDG-I samples was decreased to variable extents depending on the of N-glycosylation sites analyzed. In transferrin, the first N-glycosylation site was occupied 12 from 70% to 96%, whereas the occupancy of second N-glycosylation site was reduced down to 41% in CDG-I samples (Table 3) . Generally, the second transferrin glycosylation site was less occupied than the first site, indicating a preferred glycosylation of the first site in this glycoprotein. The underglycosylation level of α1-antitrypsin was less pronounced than that of transferrin in CDG-I. In α1-antitrypsin, the second N-glycosylation site showed the strongest reduction, down to 65% occupancy, whereas the first and third sites were hardly altered, showing occupancies between 94-100% and 89-100%, respectively ( Table 3 ). The site occupancy of the first α1-antitrypsin N-glycosylation site could not be determined in every sample, possibly due to low ionization efficiencies of the triply charged peptide in the ion source. Additionally, this peptide contains N-terminal glutamine, which can circularize to pyroglutamic acid and a methionine residue which can oxidize to methionine sulfoxide, thus evading detection via the MRM transitions applied. The occupancy of transferrin N-glycosylation sites in HFI and in alcohol abuse samples were not as pronounced as in CDG-I samples, yet like in CDG-I, the second site was less glycosylated than the first one. The N-glycosylation of α1-antitrypsin was hardly reduced in the HFI and alcohol abuse samples investigated ( Table 3) . As expected, Nglycosylation site occupancy was unchanged in CDG-II samples, which are characterized by defects of glycan trimming and elongation. The N-glycosylation site occupancies of transferrin and α-1-antitrypsin were determined with high precision as illustrated by the standard deviations obtained. The maximum deviation reached 10.8 % in one out of the 28 serum samples analysed.
The standard deviations calculated for the other samples ranged from 0.0 to 7.8 % per glycosylation site. The highest accuracy was obtained in the CDG-II, HFI, alcohol abuse and healthy control samples. In these samples the maximum standard deviation was calculated to be 2.5 % ( Table 3 ). The reasons for the higher deviations in the measurements of the N-13 glycosylation site occupancies of the CDG-I sera are not clear. Possibly, lower serum protein levels as observed in CDG-I patients contribute to this observation. Table 3 From all N-glycosylation sites investigated the second transferrin site appeared to respond most sensitively to defects of glycosylation. Clinical information was available for 11 CDG-I cases investigated here and we grouped these cases into three groups of patients displaying severe, moderate and mild clinical manifestation (11) . A clear correlation between the occupancy of the second transferrin N-glycosylation site and the severity of CDG-I condition could be observed (Fig. 5) . The lowest level of site occupancy detected in CDG-I samples never reached less than 40%. A minor reduction of N-glycosylation site occupancy to about 85% of normal levels as seen in transferrin was already compatible with a disease state, indicating that N-glycosylation site occupancy is stringently required for proper physiological function of glycoproteins. ATP1D, first α1-antitrypsin N-glycosylation site; ATP2D, second α1-antitrypsin N-glycosylation site; ATP3D, third α1-antitrypsin N-glycosylation site.
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